The 31 references in paper A. Stamo P., K. Belyakov M., V. Grigoryeva N., Yu. Avdonina D., А. Стамо П., В. Григорьева Н., К. Беляков М., Ю. Авдонина Д. (2015) “ОСОБЕННОСТИ ПОРАЖЕНИЯ ПЕРИФЕРИЧЕСКОЙ НЕРВНОЙ СИСТЕМЫ ПРИ МНОЖЕСТВЕННОЙ МИЕЛОМЕ // THE PATTERN OF PERIPHERAL NERVOUS SYSTEM DETERIORATION IN MULTIPLE MYELOMA” / spz:neicon:nevro:y:2013:i:2:p:4-10

1
Андреева Н.Е. Диагностика и лечение множественной миеломы: Методическое пособие. М.: Право на жизнь, Эребус, 1994.
(check this in PDF content)
2
Байков В.В. Морфологическая диагностика плазмоцитарной миеломы по трепанобиопсиям: (гистологические и иммуногистохимические критерии). // Арх. пат. — 2007. — No 2. — С. 50 — 52.
(check this in PDF content)
3
Гехт Б.М. Теоретическая и клиническая электромиография. — Л.: Наука, 1990.
(check this in PDF content)
4
Голубева В.В., Мозолевский Ю.В., Азимова Ю.Э., Беляев А.А. Полиневропатия в структуре POEMS-синдрома при остеосклеротической форме миеломной болезни // Неврол. журн. — 2003. — Т. 8, No 1. — С. 32—36.
(check this in PDF content)
5
Argyriou A.A. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature // Blood. — 2008. — Vol. 112, N 5. — P. 1593—1599.
(check this in PDF content)
6
Bajawa H.P.S., Kelly J.J. Primary systemic amyloid neuropathy // Primary Systemic Amyloid Neuropathy / Ed.: J. E. Karp. — Humana Press, 2010. — Chapt. 10, P. 145—148.
(check this in PDF content)
7
Becker P.S. Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma // J. Clin. Oncol. — 2011. — Vol. 29, N 7. — P. 783—786.
(check this in PDF content)
8
Beijers A.J.M. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies // Netherlands J. Med. — 2012. — Vol. 70, N 1. — P. 18—25.
(check this in PDF content)
9
Bosch E.P. Smith B.E. Peripheral neuropathies associated with monoclonal proteins // Med. Clin. N. Am. — 1993. — Vol. 77, N 1. — P. 125—139.
(check this in PDF content)
10
Camacho J., Arnalich F., Anciones B. et al. The spectrum of neurological manifestations in myeloma // J. Med. — 1985. — Vol. 16, N 5—6. — P. 597—611.
(check this in PDF content)
11
Cavaletti G., Gilardini A., Canta A. et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat // Exp. Neurol. — 2007. — Vol. 204, N 1. — P. 317—325.
(check this in PDF content)
12
Chacko J.M. Paraproteinemic neuropathies // J. Clin. Neuromuscul. Dis. — 2006. — Vol. 7, N 4. — P. 185—197.
(check this in PDF content)
13
Chim C.S., Wong L.G. Deafness associated with the use of Bortezomib in multiple myeloma // Acta Oncol. — 2008. — Vol. 47, N 2. — P. 323—324.
(check this in PDF content)
14
Corso A., Mangiacavalli S., Varettoni M. et al. Bortezomibinduced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients // J. Pain. — 2007. — Vol. 8, N 4. — P. 296—306.
(check this in PDF content)
15
Dispenzieri A., Gertz M.A. Treatment options for POEMS syndrome // Expert Opin. Pharmacother. — 2005. — Vol. 6, N 6. — P. 945—953.
(check this in PDF content)
16
Haan J., Peters W.G. Amyloid and peripheral nervous system disease // Clin. Neurol. Neurosurg. — 1994. — Vol. 96, N 1. — P. 1—9.
(check this in PDF content)
17
Hájek R., Krejcí M., Pour L., Adam Z. Multiple myeloma // Klin. Onkol. — 2011. — Vol. 24. — P. 11—13.
(check this in PDF content)
18
Joshi A., Jiang D., Singh P., Moffat D. Skull base presentation of multiple myeloma // Ear Nose Throat. — 2011. — Vol. 90, N 1. — P. 6—9.
(check this in PDF content)
19
Kyle R.A., Gertz M.A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases // Semin. Hematol. — 2011. — Vol. 32. — P. 45—59.
(check this in PDF content)
20
Na J.H., Park S.H., Shin S.Y. Multiple myeloma manifesting as a fl uctuating sixth nerve palsy // Korean J. Ophthalmol. — 2009. — Vol. 23, N 3. — P. 232—233.
(check this in PDF content)
21
Rajabally Y.A. Neuropathy and paraproteins: review of a complex association // Eur. J. Neurol. — 2011. — Vol. 18, N 11. — P. 1291—1298.
(check this in PDF content)
22
Ravaglia S., Corso A., Piccolo G. et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib // Clin. Neurophysiol. — 2008. — Vol. 119, N 11. — P. 2507—2512.
(check this in PDF content)
23
Richardson P.G., Briemberg H., Jagannath S. et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib // J. Clin. Oncol. — 2006. — Vol. 24, N 19. - P. 3113—3120.
(check this in PDF content)
24
Samanta A., Hilton D., Roy S. Peripheral neuropathy, polymyalgia and arthralgia: a paraneoplastic syndrome associated with myeloma // Clin. Rheumatol. — 1990. — Vol. 9, N 2. — P. 246—248.
(check this in PDF content)
25
Shimura K., Shimazaki C., Taniguchi K. Bortezomib-induced neurogenic bladder in patients with multiple myeloma // Ann. Hematol. — 2009. — Vol. 88, N 4. — P. 383—384.
(check this in PDF content)
26
Simmons Z. Paraproteinemia and neuropathy // Curr. Opin. Neurol. — 1999. — Vol. 12, N 5. — P. 589—595.
(check this in PDF content)
27
Sonneveld P., Jongen J.L.M. Dealing with neuropathy in plasmacell dyscrasias // Hematology. Am. Soc. Hematol. Educ. Progr. — 2010. — Vol. 2010. — P. 423—430.
(check this in PDF content)
28
Verghese J.P., Bradley W.G., Nemni R., McAdam K.P. Amyloid neuropathy in multiple myeloma and other plasma cell dyscrasias. A hypothesis of the pathogenesis of amyloid neuropathies // J. Neurol. Sci. — 1983. — Vol. 59, N 2. — P. 237—246.
(check this in PDF content)
29
Vermeiren P., Vantilborgh A., Offner F. Myeloma of the central nervous system: report of a single center case series // Acta Clin. Belg. — 2011. — Vol. 66, N 3. — P. 205—208.
(check this in PDF content)
30
Wicklund M.P., Kissel J.T. Paraproteinemic Neuropathy // Curr. Treat. Options Neurol. — 2001. — Vol. 3, N 2. — P. 147—156.
(check this in PDF content)
31
Willison H.J., Yuki N. Peripheral neuropathies and antiglycolipid antibodies // Brain. — 2002. — Vol. 125, N 12. — P. 2591—2625.
(check this in PDF content)